The luxury market may have cooled in China, but contemporary players are gaining ground with clever strategies aimed at amplifying retail and building community and brand awareness.

Saphyre, Inc., an industry award winning fintech company using patent-approved technology to solve pre-trade activities and post-trade issues, announces that Ninety One has joined its network of ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF345.00. The company’s shares closed ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision loss in adults with diabetes ...

Ali Roche has been appointed director of LUX. Roche is currently chief curator at Nottingham Contemporary and was previously ...

Georgia Roche is set to make her first England appearance in 16 months after being named in a squad to face Australia that ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust ...

1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Kadcyla was launched in the UK in February, and in its corporate financial results for the first quarter of 2014, Roche proclaimed that Kadcyla had enjoyed strong uptake in Germany and the UK in ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo ... a “clinical consensus by leading UK experts.” Though the PMCPA’s ...